Physician profile
Thomas Copperman
NPI 1710220330
$1,774.06
in general payments reported to CMS, 2019-2025
12 companies · $677 in 2025
The $677 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $163 · 2020: $30.42 · 2021: $80.96 · 2022: $222 · 2023: $341 · 2024: $260 · 2025: $677.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,278.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,277.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $433.10 | 2021-2025 | Cequa |
| Amgen INC. | $343.92 | 2024-2025 | Tepezza |
| Horizon Therapeutics Plc | $318.99 | 2020-2023 | Tepezza |
| Dompe US, INC. | $234.19 | 2025 | Oxervate |
| Galderma Laboratories, L.P. | $146.64 | 2019 | |
| Bausch & Lomb Americas INC. | $106.46 | 2024-2025 | Miebo, Xiidra, Vyzulta |
| Thea Pharma INC. | $56.37 | 2022-2025 | Iyuzeh |
| Tarsus Pharmaceuticals, INC. | $41.67 | 2024 | Xdemvy |
| Johnson & Johnson Surgical Vision, INC. | $35.00 | 2023 | Lipiflow System Activator (Disposable) |
| Abbvie INC. | $25.29 | 2024 | |
| Solta Medical, A Division of Bausch Health US, LLC | $16.53 | 2019 | |
| Oyster Point Pharma, INC. | $15.90 | 2023 | Tyrvaya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Copperman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.